|
Information on Gadolinium-Containing Contrast Agents
| The issue described in this communication has been addressed in product labeling, please see Drugs@FDA |
The U.S. Food and Drug Administration (FDA) has asked manufacturers to include a new boxed warning on the product labeling of all gadolinium-based contrast agents which are used to enhance the quality of magnetic resonance imaging (MRI).
Gadolinium-Containing Contrast Agents: Labeling and Regulatory History from Drugs@FDA
Historical Information
 Back
to Top 
Back to Drug Index
 PDF requires the free Adobe
Acrobat Reader
Date created: June 8, 2006; updated May 23, 2007 |
